PPAR-γ agonists and diabetic nephropathy

被引：25
|
作者：
Zhang Y. [1 ]
Guan Y. [1 ]
机构：
[1] Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville
来源：
Current Diabetes Reports | 2005年 / 5卷 / 6期
关键词：
Diabetic Nephropathy; Rosiglitazone; Pioglitazone; Mesangial Cell; Troglitazone;
D O I：
10.1007/s11892-005-0057-5
中图分类号：
学科分类号：
摘要：
Diabetic nephropathy is a clinical syndrome of albuminuria, declining glomerular filtration rate, and increased risk of cardiovascular disease. Multiple mechanisms have been implicated in its pathogenesis. Although current therapies appear to be effective, treatment of diabetic nephropathy remains suboptimal. This review summarizes the recently emerging evidence suggesting that peroxisome proliferator-activated receptor-γ agonists may prove to be effective therapeutic agents in the treatment of diabetic renal complications. Copyright © 2005 by Current Science Inc.
引用
收藏
页码：470 / 475
页数：5
相关论文
共 50 条
  • [1] PPAR agonists in diabetic nephropathy - Reply
    Boulanger, Henri
    Mansouri, Rafik
    Gautier, Jean Francois
    Glotz, Denis
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (07) : 2095 - 2096
  • [2] PPAR-α and PPAR-γ agonists for type 2 diabetes
    Charbonnel, Bernard
    LANCET, 2009, 374 (9684): : 96 - 98
  • [3] New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy
    Jia, Zhanjun
    Sun, Ying
    Yang, Guangrui
    Zhang, Aihua
    Huang, Songming
    Heiney, Kristina Marie
    Zhang, Yue
    PPAR RESEARCH, 2014, 2014
  • [4] QSAR analysis of PPAR-γ agonists as anti-diabetic agents
    Dixit, Anshuman
    Saxena, Anil K.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2008, 43 (01) : 73 - 80
  • [5] Three-in-one agonists for PPAR-α, PPAR-γ, and PPAR-δ from traditional Chinese medicine
    Chen, Kuan-Chung
    Chang, Su-Sen
    Huang, Hung-Jin
    Lin, Tu-Liang
    Wu, Yong-Jiang
    Chen, Calvin Yu-Chian
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2012, 30 (06): : 662 - 683
  • [6] PPAR-γ receptor agonists—a review of their role in diabetic management in Trinidad and Tobago
    Steve Ian Smith
    Molecular and Cellular Biochemistry, 2004, 263 : 189 - 210
  • [7] PPAR-γ receptor agonists -: a review of their role in diabetic management in Trinidad and Tobago
    Smith, SI
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2004, 263 (01) : 189 - 210
  • [8] Fructus arctii mitigates diabetic nephropathy via the Apoh/ PPAR-γ pathway
    Zhang, Na
    Chen, Anhui
    Dong, Yuwei
    Dou, Deqiang
    MOLECULAR IMMUNOLOGY, 2025, 181 : 18 - 28
  • [9] PPAR-α and -γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse
    Calkin, Anna C.
    Giunti, Sara
    Jandeleit-Dahm, Karin A.
    Allen, Terri J.
    Cooper, Mark E.
    Thomas, Merlin C.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (09) : 2399 - 2405
  • [10] PPAR-γ agonists modulate lipid composition and glomerulosclerosis in ZDF diabetic rats.
    Halaihel, N
    Goldstein, BL
    Jiang, T
    Villanueva, R
    Phelix, C
    Levi, M
    JOURNAL OF INVESTIGATIVE MEDICINE, 2004, 52 (01) : S137 - S137
12345